Physician profile
Nishanth Sukumaran
NPI 1538328844
$7,117.45
in general payments reported to CMS, 2019-2025
63 companies · $2,280 in 2025
The $2,280 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $87.96 · 2020: $22.31 · 2021: $11.92 · 2022: $744 · 2023: $1,975 · 2024: $1,997 · 2025: $2,280.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,252.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,251.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $570.31 | 2022-2025 | Calquence, Lynparza, Tagrisso |
| Genentech USA, INC. | $508.54 | 2022-2025 | Tecentriq, Alecensa, Venclexta |
| Novartis Pharmaceuticals Corporation | $507.94 | 2019-2025 | |
| Pfizer INC. | $429.93 | 2019-2025 | |
| Eisai INC. | $420.35 | 2022-2025 | |
| Janssen Biotech, INC. | $390.65 | 2020-2025 | Darzalex, Tecvayli, Talvey |
| E.R. Squibb & Sons, L.L.C. | $375.37 | 2022-2025 | Opdivo, Opdualag |
| Incyte Corporation | $312.23 | 2022-2025 | Jakafi, Monjuvi, Zynyz |
| Genzyme Corporation | $198.50 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $193.70 | 2022-2025 | Fruzaqla, Alunbrig, Vpriv |
| Merck Sharp & Dohme LLC | $192.83 | 2023-2025 | Keytruda, Lynparza, Welireg |
| Bayer Healthcare Pharmaceuticals INC. | $159.99 | 2023-2025 | |
| Taiho Oncology, INC. | $159.80 | 2022-2025 | |
| Celgene Corporation | $158.46 | 2022-2025 | Reblozyl, Pomalyst |
| Regeneron Healthcare Solutions, INC. | $156.32 | 2022-2025 | Libtayo, Lynozyfic |
Show all 63 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $124.14 | 2023-2024 | Xospata, Vyloy, Xtandi |
| Pharmacyclics LLC, An Abbvie Company | $121.47 | 2022-2023 | Imbruvica, Epkinly |
| Novocure INC. | $119.57 | 2023 | Optune |
| Lilly USA, LLC | $100.66 | 2023-2025 | Jaypirca, Verzenio, Retevmo |
| Legend Biotech USA INC. | $96.42 | 2024-2025 | Carvykti |
| Glaxosmithkline, LLC. | $91.44 | 2023-2025 | Ojjaara, Blenrep |
| Mirati Therapeutics, INC. | $90.75 | 2023-2024 | Krazati |
| Servier Pharmaceuticals LLC | $90.63 | 2023-2025 | |
| Ipsen Biopharmaceuticals, INC | $72.16 | 2022-2025 | Onivyde |
| Stemline Therapeutics INC. | $71.90 | 2023-2025 | Orserdu |
| Adaptive Biotechnologies Corporation | $71.83 | 2022-2025 | Clonoseq |
| Daiichi Sankyo INC. | $71.83 | 2022 | |
| Abbvie INC. | $69.23 | 2025 | |
| Pharmacosmos Therapeutics INC. | $67.32 | 2023-2025 | Monoferric |
| Octapharma USA, INC. | $64.62 | 2023-2025 | Octagam Immune Globulin (Human) |
| Seagen INC. | $59.91 | 2019-2023 | Tukysa |
| Kite Pharma, INC. | $56.15 | 2023 | Yescarta |
| Puma Biotechnology, INC. | $55.03 | 2023-2024 | |
| Adc Therapeutics America, INC. | $53.23 | 2024-2025 | |
| Rigel Pharmaceuticals, INC. | $50.11 | 2025 | Tavalisse, Rezlidhia, Gavreto |
| Sobi, INC | $48.29 | 2024-2025 | |
| Emd Serono, INC. | $47.50 | 2023 | Tepmetko, Bavencio |
| Sumitomo Pharma America, INC. | $44.68 | 2024-2025 | Orgovyx |
| Fennec Pharmaceuticals, INC. | $44.23 | 2024 | Pedmark |
| Amgen INC. | $41.34 | 2022-2023 | Kyprolis, Blincyto |
| Genmab U.S., INC. | $35.96 | 2024 | Epkinly |
| Beigene USA, INC. | $35.36 | 2023-2024 | Brukinsa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.36 | 2024-2025 | Gilotrif |
| Horizon Therapeutics Plc | $32.85 | 2022 | |
| Agios Pharmaceuticals, INC. | $29.63 | 2025 | Pyrukynd |
| Alexion Pharmaceuticals, INC. | $28.11 | 2024 | Ultomiris |
| Azurity Pharmaceuticals, INC. | $27.93 | 2025 | Danziten, Vivimusta |
| Coherus Oncology, INC. | $27.36 | 2023 | |
| Gilead Sciences, INC. | $26.77 | 2021-2022 | |
| Alnylam Pharmaceuticals INC. | $25.02 | 2023 | Givlaari |
| Caris Mpi, INC. | $24.05 | 2025 | Mi Cancer Seek |
| Blueprint Medicines Corporation | $23.59 | 2024 | Ayvakit |
| Morphosys, US INC. | $21.93 | 2024 | Monjuvi |
| Karyopharm Therapeutics INC. | $21.35 | 2025 | Xpovio |
| Pharmaessentia USA Corporation | $20.82 | 2023 | Besremi |
| Cti Biopharma Corp. | $20.51 | 2022 | |
| Array Biopharma INC | $19.90 | 2023 | Lorbrena, Braftovi, Mektovi |
| G1 Therapeutics, INC. | $19.65 | 2023 | Cosela |
| Exelixis INC. | $18.97 | 2023 | Cabometyx |
| Apellis Pharmaceuticals, INC. | $17.16 | 2023 | Empaveli |
| Tersera Therapeutics LLC | $16.85 | 2023 | Xermelo |
| Accord Healthcare, INC. | $15.74 | 2025 | |
| Tactile Systems Technology INC | $15.22 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nishanth Sukumaran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.